Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating […]
